Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2022 | $43.00 → $20.00 | Buy | HC Wainwright & Co. |
| 11/16/2021 | $46.00 → $43.00 | Buy | HC Wainwright & Co. |
| 7/27/2021 | $28.00 | Overweight | Stephens & Co. |
Pulse Biosciences, Inc. (NASDAQ:PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to present at the upcoming TD Cowen 45th Annual Health Care Conference in Boston. Pulse Biosciences' Management is scheduled to present on Wednesday, March 5, 2025, at 10:30 am ET. A live and recorded webcast of the presentation will be available on the "Events Calendar and Presentations" page of the company's investor website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve
Expanded executive team to support operational excellence and commercialization of the CellFX nanosecond PFA Platform Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025. "I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled public diversified medtech companies will be extremely valuable in our efforts to advance our nanosecon
Successfully treated atrial fibrillation (AF) in initial 30 patients with the Nanosecond PFA 360° Cardiac Catheter Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late-breaking data from its Nanosecond PFA 360° Cardiac Catheter System first-in-human feasibility study, which data were recently presented at the 30th Annual AF Symposium 2025 meeting. The feasibility study is intended to assess the initial safety and efficacy of the Nanosecond PFA 360° Cardiac Catheter System for the treatment of AF (NCT06696170). To date, 77 patients have been treated by six investigators, inclu
Expanded executive team to support operational excellence and commercialization of the CellFX nanosecond PFA Platform Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025. "I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled public diversified medtech companies will be extremely valuable in our efforts to advance our nanosecon
Adds Andrea Natale, M.D. as a medical advisor, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D. Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D., who altogether will continue to support the development and clinical efforts for the Pulse Biosciences nano-PFA 360 Cardiac Catheter. "I am inspired by the potential of nano-PFA and the unique catheter
Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed Co-Chairman of the Board alongside Co-Chairman Robert W. Duggan, serving as an independent director. "We are thrilled to have Paul join the Pulse Biosciences Board. His track record speaks for itself as he has been influential in the medical tech
Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA or nano-PFA) technology, today announced business updates and financial results for the third quarter ended September 30, 2024. Recent Business Highlights Soft Tissue Ablation Placed nsPFA Percutaneous Electrode Systems with seven sites in the U.S. as part of a pilot program for clinical assessment with commercial use expected to begin in the coming quarters. The Company expects to commence a pivotal clinical trial in mid-2025 to support a specific labeling indication to commercialize the Percutaneous Electrode System in
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-877-407-0752 for domestic callers or 1-201-389-0912 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medi
Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA) technology, today announced business updates and preliminary financial results for the second quarter ended June 30, 2024. Recent Business Highlights Soft Tissue Ablation Completed the first procedure with the Percutaneous Electrode System in the United States following U.S. FDA 510(k) clearance for the ablation of soft tissue and subsequently completed cases at five sites across the United States. The Company expects to commence a pivotal clinical trial in 2025 to support a specific labeling indication to commerc
HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $20.00 from $43.00 previously
HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $43.00 from $46.00 previously
Stephens & Co. initiated coverage of Pulse Biosciences with a rating of Overweight and set a new price target of $28.00
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
SC 13D/A - PULSE BIOSCIENCES, INC. (0001625101) (Subject)
SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)
SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)
8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)